<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>VECVO — The Science of Not Dying</title>
<meta name="description" content="VECVO is a longevity science research hub dedicated to conquering biological aging. Founded by Alice Frolov.">
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Bebas+Neue&family=Cormorant+Garamond:ital,wght@0,300;0,400;0,600;1,300;1,400&family=DM+Mono:ital,wght@0,300;0,400;1,300&display=swap" rel="stylesheet">
<style>
:root {
  --void: #03040a;
  --deep: #07090f;
  --panel: #0b0e18;
  --border: rgba(0,210,220,0.09);
  --accent: #00d4dc;
  --accent2: #00ffcc;
  --gold: #c9a84c;
  --white: #eef2ff;
  --muted: #6b7a94;
  --text: #b8c4da;
}

*, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
html { scroll-behavior: smooth; }

body {
  background: var(--void);
  color: var(--text);
  font-family: 'Cormorant Garamond', serif;
  font-size: 18px;
  overflow-x: hidden;
  cursor: none;
}
@media (pointer: coarse) {
  body { cursor: auto; }
  #cursor, #cursorRing { display: none; }
}

/* ── CURSOR ── */
#cursor {
  width: 6px; height: 6px;
  background: var(--accent);
  border-radius: 50%;
  position: fixed;
  pointer-events: none;
  z-index: 9999;
  mix-blend-mode: screen;
  transition: transform 0.1s;
}
#cursorRing {
  width: 36px; height: 36px;
  border: 1px solid rgba(0,212,220,0.35);
  border-radius: 50%;
  position: fixed;
  pointer-events: none;
  z-index: 9998;
  transition: all 0.14s ease;
  transform: translate(-50%,-50%);
}

/* ── NOISE ── */
body::before {
  content: '';
  position: fixed; inset: 0;
  background-image: url("data:image/svg+xml,%3Csvg viewBox='0 0 256 256' xmlns='http://www.w3.org/2000/svg'%3E%3Cfilter id='n'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.85' numOctaves='4' stitchTiles='stitch'/%3E%3C/filter%3E%3Crect width='100%25' height='100%25' filter='url(%23n)' opacity='0.035'/%3E%3C/svg%3E");
  opacity: 0.5; pointer-events: none; z-index: 1;
}

/* ── NAV ── */
nav {
  position: fixed;
  top: 0; left: 0; right: 0;
  z-index: 100;
  padding: 22px 56px;
  display: flex;
  justify-content: space-between;
  align-items: center;
  background: linear-gradient(to bottom, rgba(3,4,10,0.96), transparent);
}

.logo {
  font-family: 'DM Mono', monospace;
  font-weight: 400;
  font-size: 13px;
  letter-spacing: 0.5em;
  color: var(--white);
  text-decoration: none;
  display: flex;
  align-items: center;
  gap: 14px;
  text-transform: uppercase;
}

/* VECVO logo mark — the V mirror symbol */
.vecvo-mark {
  width: 34px; height: 34px;
  position: relative;
  flex-shrink: 0;
}
.vecvo-mark svg {
  width: 100%; height: 100%;
}

.nav-links {
  display: flex; gap: 36px; list-style: none;
}
.nav-links a {
  font-family: 'DM Mono', monospace;
  font-size: 10px; letter-spacing: 0.2em;
  color: var(--muted);
  text-decoration: none; text-transform: uppercase;
  transition: color 0.25s;
}
.nav-links a:hover { color: var(--accent); }

/* ── HERO ── */
.hero {
  min-height: 100vh;
  display: flex; flex-direction: column;
  justify-content: center; align-items: center;
  text-align: center;
  position: relative; overflow: hidden;
  padding: 130px 40px 100px;
}

.hero-bg {
  position: absolute; inset: 0;
  background:
    radial-gradient(ellipse 70% 55% at 50% 105%, rgba(0,80,90,0.45) 0%, transparent 65%),
    radial-gradient(ellipse 50% 35% at 15% 15%, rgba(0,212,220,0.05) 0%, transparent 60%),
    radial-gradient(ellipse 30% 25% at 85% 25%, rgba(0,255,204,0.03) 0%, transparent 50%),
    var(--void);
}

.grid-overlay {
  position: absolute; inset: 0;
  background-image:
    linear-gradient(rgba(0,212,220,0.025) 1px, transparent 1px),
    linear-gradient(90deg, rgba(0,212,220,0.025) 1px, transparent 1px);
  background-size: 72px 72px;
  animation: gridDrift 24s linear infinite;
}
@keyframes gridDrift {
  0%   { transform: translateY(0); }
  100% { transform: translateY(72px); }
}

/* Big VECVO hero mark */
.hero-symbol {
  position: relative; z-index: 2;
  margin-bottom: 52px;
  animation: riseIn 1s 0.1s both;
}

.hero-vecvo-ring {
  width: 140px; height: 140px;
  margin: 0 auto 28px;
  position: relative;
}

.hero-eyebrow {
  font-family: 'DM Mono', monospace;
  font-size: 10px; letter-spacing: 0.45em;
  color: var(--accent); text-transform: uppercase;
  margin-bottom: 28px;
  position: relative; z-index: 2;
  animation: riseIn 1s 0.2s both;
}
.hero-eyebrow::before { content: '◇ '; }
.hero-eyebrow::after  { content: ' ◇'; }

h1 {
  font-family: 'Bebas Neue', sans-serif;
  font-size: clamp(72px, 11vw, 156px);
  font-weight: 400;
  line-height: 0.88;
  color: var(--white);
  position: relative; z-index: 2;
  animation: riseIn 1s 0.35s both;
  letter-spacing: 0.06em;
}
h1 .accent-word {
  color: var(--accent);
  display: block;
  font-size: 0.7em;
  letter-spacing: 0.12em;
}

.hero-sub {
  max-width: 560px;
  margin: 36px auto 0;
  font-size: 19px; font-weight: 300;
  color: var(--muted); line-height: 1.9;
  position: relative; z-index: 2;
  animation: riseIn 1s 0.5s both;
}

.hero-cta {
  display: flex; gap: 18px;
  margin-top: 56px;
  position: relative; z-index: 2;
  animation: riseIn 1s 0.7s both;
  flex-wrap: wrap; justify-content: center;
}

.btn-primary {
  font-family: 'DM Mono', monospace;
  font-size: 11px; letter-spacing: 0.22em;
  text-transform: uppercase;
  padding: 15px 38px;
  background: var(--accent); color: var(--void);
  border: none; text-decoration: none;
  font-weight: 400; transition: all 0.28s;
  position: relative; overflow: hidden;
}
.btn-primary::before {
  content: '';
  position: absolute; inset: 0;
  background: var(--accent2);
  transform: translateX(-100%);
  transition: transform 0.28s;
}
.btn-primary:hover::before { transform: translateX(0); }
.btn-primary span { position: relative; z-index: 1; }

.btn-ghost {
  font-family: 'DM Mono', monospace;
  font-size: 11px; letter-spacing: 0.22em;
  text-transform: uppercase;
  padding: 15px 38px;
  background: transparent; color: var(--white);
  border: 1px solid rgba(255,255,255,0.14);
  text-decoration: none; transition: all 0.28s;
}
.btn-ghost:hover { border-color: var(--accent); color: var(--accent); }

.scroll-hint {
  position: absolute; bottom: 36px; left: 50%;
  transform: translateX(-50%);
  z-index: 2; display: flex; flex-direction: column;
  align-items: center; gap: 8px;
  animation: riseIn 1s 1.1s both;
}
.scroll-bar {
  width: 1px; height: 56px;
  background: linear-gradient(to bottom, transparent, var(--accent));
  animation: scrollPulse 2.2s ease-in-out infinite;
}
@keyframes scrollPulse {
  0%   { transform: scaleY(0); transform-origin: top; }
  50%  { transform: scaleY(1); transform-origin: top; }
  51%  { transform: scaleY(1); transform-origin: bottom; }
  100% { transform: scaleY(0); transform-origin: bottom; }
}

@keyframes riseIn {
  from { opacity: 0; transform: translateY(28px); }
  to   { opacity: 1; transform: translateY(0); }
}

/* ── STAT BAR ── */
.stat-bar {
  background: var(--deep);
  border-top: 1px solid var(--border);
  border-bottom: 1px solid var(--border);
  padding: 36px 60px;
  display: grid;
  grid-template-columns: repeat(4, 1fr);
  gap: 0;
}
.stat-item {
  text-align: center;
  padding: 8px 24px;
  border-right: 1px solid var(--border);
}
.stat-item:last-child { border-right: none; }
.stat-num {
  font-family: 'Bebas Neue', sans-serif;
  font-size: clamp(36px, 4.5vw, 60px);
  color: var(--white); display: block;
  letter-spacing: 0.04em; line-height: 1;
}
.stat-num b { color: var(--accent); }
.stat-label {
  font-family: 'DM Mono', monospace;
  font-size: 9px; letter-spacing: 0.22em;
  color: var(--muted); text-transform: uppercase;
  display: block; margin-top: 6px;
}

/* ── GENERIC SECTION ── */
section { padding: 120px 60px; position: relative; }

.section-tag {
  font-family: 'DM Mono', monospace;
  font-size: 9px; letter-spacing: 0.35em;
  color: var(--accent); text-transform: uppercase;
  display: flex; align-items: center; gap: 14px;
  margin-bottom: 28px;
}
.section-tag::after {
  content: ''; flex: 1; max-width: 48px;
  height: 1px; background: var(--accent); opacity: 0.35;
}

h2 {
  font-family: 'Cormorant Garamond', serif;
  font-size: clamp(38px, 5.5vw, 76px);
  font-weight: 300; color: var(--white);
  line-height: 1; margin-bottom: 56px;
  letter-spacing: -0.015em;
}
h2 em { font-style: italic; color: var(--accent); }

/* ── ABOUT ── */
.about-section {
  background: var(--deep);
  display: grid; grid-template-columns: 1fr 1fr;
  gap: 80px; align-items: center;
}
.about-text p {
  font-size: 20px; line-height: 1.95;
  color: var(--text); margin-bottom: 22px; font-weight: 300;
}
.founder-block {
  border-left: 1px solid rgba(0,212,220,0.2);
  padding-left: 36px; margin-top: 44px;
}
.founder-name {
  font-family: 'DM Mono', monospace;
  font-size: 14px; font-weight: 400;
  color: var(--white); letter-spacing: 0.18em; text-transform: uppercase;
}
.founder-role {
  font-family: 'DM Mono', monospace;
  font-size: 10px; letter-spacing: 0.2em;
  color: var(--accent); text-transform: uppercase;
  margin-top: 5px; display: block;
}
.founder-bio {
  font-size: 15px; color: var(--muted);
  line-height: 1.85; margin-top: 14px;
}

/* About visual — animated molecule */
.about-visual {
  position: relative; height: 480px;
  display: flex; align-items: center; justify-content: center;
}
.molecule {
  position: relative;
  width: 220px; height: 380px;
}

/* ── HALLMARKS ── */
.hallmarks-section { background: var(--void); }
.hallmarks-grid {
  display: grid;
  grid-template-columns: repeat(3, 1fr);
  gap: 2px;
  background: var(--border);
  border: 1px solid var(--border);
}
.hallmark-card {
  background: var(--void);
  padding: 36px;
  position: relative; overflow: hidden;
  transition: background 0.3s;
}
.hallmark-card::after {
  content: '';
  position: absolute; top: 0; left: 0; right: 0;
  height: 2px; background: var(--accent);
  transform: scaleX(0); transform-origin: left;
  transition: transform 0.35s;
}
.hallmark-card:hover { background: var(--panel); }
.hallmark-card:hover::after { transform: scaleX(1); }
.hallmark-num {
  font-family: 'DM Mono', monospace;
  font-size: 9px; color: var(--accent);
  letter-spacing: 0.2em; margin-bottom: 18px; opacity: 0.55;
}
.hallmark-card h3 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 23px; font-weight: 400;
  color: var(--white); margin-bottom: 14px; line-height: 1.2;
}
.hallmark-card p { font-size: 14px; color: var(--muted); line-height: 1.7; }

/* ── INTERVENTIONS ── */
.interventions-section { background: var(--deep); }
.tabs {
  display: flex; gap: 0;
  margin-bottom: 56px;
  border-bottom: 1px solid rgba(255,255,255,0.07);
  overflow-x: auto;
}
.tab-btn {
  font-family: 'DM Mono', monospace;
  font-size: 10px; letter-spacing: 0.18em;
  text-transform: uppercase; padding: 14px 28px;
  background: none; border: none; color: var(--muted);
  cursor: pointer; transition: all 0.25s; white-space: nowrap;
  border-bottom: 2px solid transparent; margin-bottom: -1px;
}
.tab-btn.active, .tab-btn:hover { color: var(--accent); border-bottom-color: var(--accent); }
.tab-content { display: none; }
.tab-content.active { display: grid; grid-template-columns: 1fr 1fr; gap: 56px; align-items: start; }
.intervention-info h3 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 42px; font-weight: 300;
  color: var(--white); margin-bottom: 22px; line-height: 1;
}
.intervention-info p { font-size: 17px; color: var(--text); line-height: 1.85; margin-bottom: 18px; }
.intervention-meta {
  display: grid; grid-template-columns: 1fr 1fr;
  gap: 16px; margin-top: 36px;
}
.meta-item {
  padding: 18px;
  border: 1px solid rgba(0,212,220,0.09);
  background: rgba(0,212,220,0.02);
}
.meta-label {
  font-family: 'DM Mono', monospace;
  font-size: 9px; letter-spacing: 0.2em;
  color: var(--accent); text-transform: uppercase;
  display: block; margin-bottom: 7px;
}
.meta-value {
  font-family: 'Cormorant Garamond', serif;
  font-size: 19px; color: var(--white);
}
.intervention-cards { display: flex; flex-direction: column; gap: 14px; }
.intervention-card {
  padding: 22px;
  border: 1px solid rgba(255,255,255,0.055);
  background: rgba(0,212,220,0.018);
  transition: all 0.25s;
}
.intervention-card:hover {
  border-color: rgba(0,212,220,0.18);
  background: rgba(0,212,220,0.035);
}
.intervention-card h4 {
  font-family: 'DM Mono', monospace;
  font-size: 12px; font-weight: 400; color: var(--white);
  letter-spacing: 0.12em; margin-bottom: 7px; text-transform: uppercase;
}
.intervention-card p { font-size: 13px; color: var(--muted); line-height: 1.65; }

/* ── ROADMAP ── */
.roadmap-section { background: var(--void); }
.timeline { position: relative; padding-left: 76px; }
.timeline::before {
  content: ''; position: absolute;
  left: 14px; top: 0; bottom: 0;
  width: 1px;
  background: linear-gradient(to bottom, var(--accent), rgba(0,212,220,0.05));
}
.timeline-item { position: relative; margin-bottom: 56px; }
.timeline-item::before {
  content: ''; position: absolute;
  left: -70px; top: 8px;
  width: 9px; height: 9px;
  border-radius: 50%; background: var(--accent);
  box-shadow: 0 0 14px rgba(0,212,220,0.65);
}
.timeline-year {
  font-family: 'DM Mono', monospace;
  font-size: 10px; color: var(--accent);
  letter-spacing: 0.22em; margin-bottom: 10px;
}
.timeline-item h3 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 30px; font-weight: 400;
  color: var(--white); margin-bottom: 14px; line-height: 1.1;
}
.timeline-item p { font-size: 15px; color: var(--muted); line-height: 1.8; max-width: 580px; }

/* ── FAQ ── */
.faq-section { background: var(--deep); }
.accordion-item { border-bottom: 1px solid rgba(255,255,255,0.055); }
.accordion-header {
  display: flex; justify-content: space-between; align-items: center;
  padding: 26px 0; cursor: pointer; transition: color 0.25s;
}
.accordion-header:hover h4 { color: var(--accent); }
.accordion-header h4 {
  font-family: 'Cormorant Garamond', serif;
  font-size: 22px; font-weight: 400;
  color: var(--white); transition: color 0.25s;
  line-height: 1.3; padding-right: 36px;
}
.accordion-icon {
  font-family: 'DM Mono', monospace;
  font-size: 18px; color: var(--accent);
  transition: transform 0.3s; flex-shrink: 0;
}
.accordion-item.open .accordion-icon { transform: rotate(45deg); }
.accordion-body { max-height: 0; overflow: hidden; transition: max-height 0.4s ease; }
.accordion-item.open .accordion-body { max-height: 400px; }
.accordion-body-inner {
  padding-bottom: 26px;
  font-size: 16px; color: var(--muted); line-height: 1.9;
}

/* ── COMPANIES ── */
.companies-section { background: var(--void); text-align: center; }
.companies-grid {
  display: grid; grid-template-columns: repeat(4, 1fr);
  gap: 2px; background: var(--border);
  border: 1px solid var(--border); margin-top: 56px;
}
.company-cell {
  background: var(--void); padding: 28px 22px;
  display: flex; flex-direction: column; gap: 7px;
  transition: background 0.25s; text-align: left;
}
.company-cell:hover { background: var(--panel); }
.company-name {
  font-family: 'DM Mono', monospace;
  font-size: 11px; font-weight: 400;
  color: var(--white); letter-spacing: 0.18em; text-transform: uppercase;
}
.company-focus {
  font-family: 'DM Mono', monospace;
  font-size: 9px; color: var(--accent);
  letter-spacing: 0.15em; text-transform: uppercase;
}
.company-desc { font-size: 13px; color: var(--muted); line-height: 1.6; margin-top: 4px; }

/* ── MANIFESTO ── */
.manifesto {
  background: var(--panel);
  border-top: 1px solid var(--border);
  border-bottom: 1px solid var(--border);
  padding: 120px 60px; text-align: center;
}
.manifesto-inner { max-width: 780px; margin: 0 auto; }
.manifesto-quote {
  font-family: 'Cormorant Garamond', serif;
  font-size: clamp(26px, 3.6vw, 44px);
  font-weight: 300; color: var(--white);
  line-height: 1.45; margin-bottom: 36px;
  font-style: italic;
}
.manifesto-quote em {
  font-style: normal; color: var(--accent);
  text-decoration: underline;
  text-decoration-color: rgba(0,212,220,0.28);
}
.manifesto-sub {
  color: var(--muted); font-size: 15px;
  max-width: 480px; margin: 0 auto 40px;
  font-family: 'DM Mono', monospace;
  letter-spacing: 0.05em; line-height: 1.9;
}

/* ── FOOTER ── */
footer {
  background: var(--void);
  padding: 56px 60px;
  border-top: 1px solid rgba(255,255,255,0.04);
  display: grid;
  grid-template-columns: auto 1fr auto;
  gap: 36px; align-items: center;
}
.footer-logo {
  font-family: 'DM Mono', monospace;
  font-size: 13px; font-weight: 400;
  color: var(--white); letter-spacing: 0.48em;
  display: flex; align-items: center; gap: 12px; text-transform: uppercase;
}
.footer-logo .f-dot {
  width: 7px; height: 7px;
  background: var(--accent); border-radius: 50%;
  box-shadow: 0 0 10px rgba(0,212,220,0.6);
}
.footer-logo span { color: var(--accent); }
.footer-center {
  font-family: 'DM Mono', monospace;
  font-size: 10px; color: var(--muted);
  letter-spacing: 0.1em; line-height: 1.85;
  text-align: center;
}
.footer-founder {
  font-family: 'DM Mono', monospace;
  font-size: 9px; color: var(--muted);
  letter-spacing: 0.18em; text-align: right;
}
.footer-founder strong {
  color: var(--white); display: block;
  font-size: 12px; letter-spacing: 0.22em;
  margin-bottom: 3px; text-transform: uppercase;
}
.footer-nav {
  display: flex; gap: 28px; justify-content: center;
  margin-top: 36px; grid-column: 1 / -1;
  border-top: 1px solid rgba(255,255,255,0.04);
  padding-top: 28px;
}
.footer-nav a {
  font-family: 'DM Mono', monospace;
  font-size: 9px; letter-spacing: 0.22em;
  color: var(--muted); text-decoration: none; text-transform: uppercase;
  transition: color 0.25s;
}
.footer-nav a:hover { color: var(--accent); }

/* ── FADE IN ── */
.fade-in {
  opacity: 0; transform: translateY(22px);
  transition: opacity 0.65s ease, transform 0.65s ease;
}
.fade-in.visible { opacity: 1; transform: translateY(0); }

/* ── MOBILE ── */
@media (max-width: 768px) {
  nav { padding: 18px 22px; }
  .nav-links { display: none; }
  section { padding: 80px 22px; }
  .stat-bar { padding: 28px 22px; grid-template-columns: repeat(2,1fr); }
  .stat-item { border-right: none; border-bottom: 1px solid var(--border); padding-bottom: 22px; }
  .stat-item:nth-child(3), .stat-item:last-child { border-bottom: none; }
  .about-section { grid-template-columns: 1fr; gap: 36px; }
  .about-visual { height: 180px; }
  .hallmarks-grid { grid-template-columns: 1fr; }
  .tab-content.active { grid-template-columns: 1fr; }
  .companies-grid { grid-template-columns: repeat(2,1fr); }
  footer { grid-template-columns: 1fr; text-align: center; }
  .footer-founder { text-align: center; }
  h1 { font-size: clamp(64px, 16vw, 120px); }
}

/* VECVO logo animation */
@keyframes vecvoSpin1 { from { transform: rotate(0); } to { transform: rotate(360deg); } }
@keyframes vecvoSpin2 { from { transform: rotate(0); } to { transform: rotate(-360deg); } }
@keyframes vecvoGlow  {
  0%,100% { opacity:1; r:8; }
  50%      { opacity:0.5; r:5; }
}
</style>
</head>
<body>
<div id="cursor"></div>
<div id="cursorRing"></div>

<!-- NAV -->
<nav>
  <a href="#" class="logo">
    <!-- VECVO mark: mirrored V's + helix dot -->
    <div class="vecvo-mark">
      <svg viewBox="0 0 34 34" fill="none" xmlns="http://www.w3.org/2000/svg">
        <circle cx="17" cy="17" r="15.5" stroke="#00d4dc" stroke-width="0.8" style="animation: vecvoSpin1 20s linear infinite; transform-origin:50% 50%"/>
        <circle cx="17" cy="17" r="10" stroke="rgba(0,212,220,0.35)" stroke-width="0.8" style="animation: vecvoSpin2 14s linear infinite; transform-origin:50% 50%"/>
        <!-- Left V -->
        <polyline points="4,10 10,24 14,15" stroke="#00d4dc" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
        <!-- Right V (mirror) -->
        <polyline points="30,10 24,24 20,15" stroke="#00d4dc" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
        <!-- Centre dot -->
        <circle cx="17" cy="17" r="2.5" fill="#00d4dc" style="animation: vecvoGlow 3s ease-in-out infinite"/>
      </svg>
    </div>
    VE<span style="color:var(--accent)">C</span>VO
  </a>
  <ul class="nav-links">
    <li><a href="#aging">Science</a></li>
    <li><a href="#interventions">Interventions</a></li>
    <li><a href="#roadmap">Roadmap</a></li>
    <li><a href="#faq">FAQ</a></li>
    <li><a href="#about">About</a></li>
  </ul>
</nav>

<!-- HERO -->
<section class="hero" id="top">
  <div class="hero-bg"></div>
  <div class="grid-overlay"></div>

  <!-- animated VECVO hero emblem -->
  <div class="hero-symbol">
    <div class="hero-vecvo-ring">
      <svg width="140" height="140" viewBox="0 0 140 140" fill="none" xmlns="http://www.w3.org/2000/svg">
        <circle cx="70" cy="70" r="66" stroke="rgba(0,212,220,0.12)" stroke-width="1" style="animation:vecvoSpin1 30s linear infinite;transform-origin:50% 50%"/>
        <circle cx="70" cy="70" r="52" stroke="rgba(0,212,220,0.2)" stroke-width="1" style="animation:vecvoSpin2 20s linear infinite;transform-origin:50% 50%"/>
        <circle cx="70" cy="70" r="38" stroke="#00d4dc" stroke-width="1.2" style="animation:vecvoSpin1 14s linear infinite;transform-origin:50% 50%"/>
        <!-- big V left -->
        <polyline points="22,38 50,100 66,62" stroke="#00d4dc" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
        <!-- big V right (mirror) -->
        <polyline points="118,38 90,100 74,62" stroke="#00d4dc" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
        <!-- centre core -->
        <circle cx="70" cy="70" r="7" fill="#00d4dc" style="animation:vecvoGlow 2.8s ease-in-out infinite"/>
        <circle cx="70" cy="70" r="14" stroke="rgba(0,212,220,0.3)" stroke-width="1" style="animation:vecvoGlow 2.8s ease-in-out infinite"/>
      </svg>
    </div>
  </div>

  <div class="hero-eyebrow" style="position:relative;z-index:2;animation:riseIn 1s 0.2s both;">Longevity Science Research Hub</div>

  <h1 style="position:relative;z-index:2;animation:riseIn 1s 0.35s both;">
    DEDICATED
    <span class="accent-word">TO LIFE</span>
  </h1>

  <p class="hero-sub">
    Aging is not a law of nature. It is a disease with identifiable mechanisms — and every mechanism has a solution. VECVO exists to accelerate that solution.
  </p>

  <div class="hero-cta">
    <a href="#aging" class="btn-primary"><span>Explore the Science</span></a>
    <a href="#about" class="btn-ghost">About Vecvo</a>
  </div>

  <div class="scroll-hint">
    <div class="scroll-bar"></div>
  </div>
</section>

<!-- STATS -->
<div class="stat-bar">
  <div class="stat-item">
    <span class="stat-num"><b id="stat1">0</b>T</span>
    <span class="stat-label">Cells in the human body</span>
  </div>
  <div class="stat-item">
    <span class="stat-num"><b id="stat2">0</b></span>
    <span class="stat-label">Hallmarks of aging</span>
  </div>
  <div class="stat-item">
    <span class="stat-num">$<b id="stat3">0</b>B+</span>
    <span class="stat-label">Longevity investment 2023</span>
  </div>
  <div class="stat-item">
    <span class="stat-num"><b id="stat4">0</b></span>
    <span class="stat-label">Target: escape velocity year</span>
  </div>
</div>

<!-- ABOUT -->
<section class="about-section" id="about">
  <div class="about-text fade-in">
    <div class="section-tag">00 — Origin</div>
    <h2>Why <em>VECVO</em> Exists</h2>
    <p>Every year, 55 million people die from age-related causes. Not from war, not from accidents — from the slow accumulation of molecular damage we once called "natural." It is not natural. It is a solvable problem.</p>
    <p>VECVO is a research hub tracking the frontier of longevity science — a living synthesis of the most consequential scientific work happening right now, built for researchers, students, and anyone who refuses to accept biological limits as permanent.</p>
    <div class="founder-block">
      <div class="founder-name">Alice Frolov</div>
      <span class="founder-role">Founder & Researcher</span>
      <p class="founder-bio">Future scientist and longevity researcher. VECVO is built on the conviction that the generation alive today may be the first to escape the mortality curve entirely.</p>
    </div>
  </div>
  <div class="about-visual fade-in">
    <!-- Animated DNA-strand SVG -->
    <svg width="200" height="380" viewBox="0 0 200 380" fill="none" xmlns="http://www.w3.org/2000/svg">
      <defs>
        <linearGradient id="dnaGrad" x1="0" y1="0" x2="0" y2="1">
          <stop offset="0%" stop-color="#00d4dc" stop-opacity="0"/>
          <stop offset="20%" stop-color="#00d4dc" stop-opacity="0.8"/>
          <stop offset="80%" stop-color="#00d4dc" stop-opacity="0.8"/>
          <stop offset="100%" stop-color="#00d4dc" stop-opacity="0"/>
        </linearGradient>
      </defs>
      <!-- Strand 1 -->
      <path d="M100,10 C140,30 60,70 100,90 C140,110 60,150 100,170 C140,190 60,230 100,250 C140,270 60,310 100,330 C140,350 60,370 100,380"
        stroke="url(#dnaGrad)" stroke-width="1.5" fill="none"
        style="animation: none"/>
      <!-- Strand 2 -->
      <path d="M100,10 C60,30 140,70 100,90 C60,110 140,150 100,170 C60,190 140,230 100,250 C60,270 140,310 100,330 C60,350 140,370 100,380"
        stroke="rgba(0,255,204,0.4)" stroke-width="1.5" fill="none"/>
      <!-- Rungs -->
      <line x1="100" y1="50" x2="100" y2="50" stroke="#00d4dc" stroke-width="1"/>
      <!-- Generated rungs via JS below -->
      <g id="dna-rungs"></g>
      <!-- Nodes -->
      <circle cx="100" cy="90" r="3" fill="#00d4dc" opacity="0.9"/>
      <circle cx="100" cy="170" r="3" fill="#00d4dc" opacity="0.9"/>
      <circle cx="100" cy="250" r="3" fill="#00d4dc" opacity="0.9"/>
      <circle cx="100" cy="330" r="3" fill="#00d4dc" opacity="0.9"/>
    </svg>
  </div>
</section>

<!-- HALLMARKS -->
<section class="hallmarks-section" id="aging">
  <div class="section-tag fade-in">01 — The Enemy</div>
  <h2 class="fade-in">12 Hallmarks of <em>Aging</em></h2>
  <div class="hallmarks-grid">
    <div class="hallmark-card fade-in"><div class="hallmark-num">01</div><h3>Genomic Instability</h3><p>Accumulated DNA damage disrupts cellular function, driving mutations and systemic dysfunction over decades.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">02</div><h3>Telomere Attrition</h3><p>Protective caps on chromosomes shorten with every cell division, eventually triggering senescence or apoptosis.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">03</div><h3>Epigenetic Alterations</h3><p>Gene expression patterns drift from their youthful state, reprogrammable via Yamanaka factor interventions.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">04</div><h3>Loss of Proteostasis</h3><p>Protein folding and clearance machinery declines, leading to toxic aggregations linked to neurodegeneration.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">05</div><h3>Disabled Macroautophagy</h3><p>The cell's self-cleaning recycling system degrades, allowing cellular debris to accumulate and impair function.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">06</div><h3>Deregulated Nutrient Sensing</h3><p>mTOR, AMPK, and insulin signaling pathways lose calibration, accelerating metabolic aging across tissues.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">07</div><h3>Mitochondrial Dysfunction</h3><p>The cell's power plants accumulate damage, producing oxidative stress that amplifies all other hallmarks.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">08</div><h3>Cellular Senescence</h3><p>Zombie cells accumulate throughout the body, secreting inflammatory signals that degrade surrounding tissues.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">09</div><h3>Stem Cell Exhaustion</h3><p>Regenerative capacity declines as stem cell pools deplete and lose functional properties needed for tissue repair.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">10</div><h3>Altered Intercellular Communication</h3><p>Signaling between cells degrades with age, disrupting coordinated tissue function and immune surveillance.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">11</div><h3>Chronic Inflammation</h3><p>Low-grade inflammaging driven by senescent cells and immune dysfunction accelerates every other hallmark.</p></div>
    <div class="hallmark-card fade-in"><div class="hallmark-num">12</div><h3>Dysbiosis</h3><p>Gut microbiome imbalance disrupts metabolism, immunity, and systemic signaling, contributing to accelerated aging.</p></div>
  </div>
</section>

<!-- INTERVENTIONS -->
<section class="interventions-section" id="interventions">
  <div class="section-tag fade-in">02 — The Arsenal</div>
  <h2 class="fade-in">Current <em>Interventions</em></h2>
  <div class="tabs fade-in">
    <button class="tab-btn active" onclick="switchTab('senolytics',event)">Senolytics</button>
    <button class="tab-btn" onclick="switchTab('reprogramming',event)">Reprogramming</button>
    <button class="tab-btn" onclick="switchTab('mtor',event)">mTOR Inhibition</button>
    <button class="tab-btn" onclick="switchTab('nad',event)">NAD+ Restoration</button>
  </div>

  <div id="tab-senolytics" class="tab-content active">
    <div class="intervention-info">
      <h3>Senolytics</h3>
      <p>Senolytics selectively eliminate senescent cells — the "zombie cells" that accumulate with age, corrupting surrounding tissue through the senescence-associated secretory phenotype (SASP).</p>
      <p>Dasatinib + Quercetin, Navitoclax, and Fisetin are the leading compounds, with multiple clinical trials now underway for age-related diseases.</p>
      <div class="intervention-meta">
        <div class="meta-item"><span class="meta-label">Status</span><span class="meta-value">Clinical Trials</span></div>
        <div class="meta-item"><span class="meta-label">Target Hallmark</span><span class="meta-value">Cellular Senescence</span></div>
        <div class="meta-item"><span class="meta-label">Animal Data</span><span class="meta-value">Strong</span></div>
        <div class="meta-item"><span class="meta-label">Human Data</span><span class="meta-value">Emerging</span></div>
      </div>
    </div>
    <div class="intervention-cards">
      <div class="intervention-card"><h4>Dasatinib + Quercetin</h4><p>First senolytic combination shown to clear senescent cells in humans. Intermittent dosing reduces systemic senescent cell burden measurably.</p></div>
      <div class="intervention-card"><h4>Navitoclax (ABT-263)</h4><p>BCL-2 family inhibitor that selectively induces apoptosis in senescent cells by targeting their anti-apoptotic survival mechanisms.</p></div>
      <div class="intervention-card"><h4>Fisetin</h4><p>Naturally occurring flavonoid with strong senolytic properties. Lower toxicity profile makes it promising for long-term intermittent use.</p></div>
    </div>
  </div>

  <div id="tab-reprogramming" class="tab-content">
    <div class="intervention-info">
      <h3>Epigenetic Reprogramming</h3>
      <p>Partial expression of Yamanaka factors can reverse epigenetic aging marks without full dedifferentiation — restoring youthful gene expression patterns in aged cells.</p>
      <p>Considered the most transformative longevity approach by many researchers, as it targets upstream information loss rather than downstream damage.</p>
      <div class="intervention-meta">
        <div class="meta-item"><span class="meta-label">Status</span><span class="meta-value">Preclinical</span></div>
        <div class="meta-item"><span class="meta-label">Target</span><span class="meta-value">Epigenetic Clock</span></div>
        <div class="meta-item"><span class="meta-label">Animal Data</span><span class="meta-value">Very Strong</span></div>
        <div class="meta-item"><span class="meta-label">Risk</span><span class="meta-value">Tumorigenesis</span></div>
      </div>
    </div>
    <div class="intervention-cards">
      <div class="intervention-card"><h4>OSK Reprogramming — Altos Labs</h4><p>$3B company developing safe partial reprogramming using Oct4, Sox2, Klf4 to restore youthful cellular identity without cancer risk.</p></div>
      <div class="intervention-card"><h4>Chemical Reprogramming</h4><p>Small molecule cocktails inducing reprogramming without viral vectors — safer and more scalable for eventual therapeutic delivery.</p></div>
      <div class="intervention-card"><h4>In Vivo Reprogramming</h4><p>AAV-delivered reprogramming factors directly into living organisms — the ultimate goal for systemic whole-body rejuvenation.</p></div>
    </div>
  </div>

  <div id="tab-mtor" class="tab-content">
    <div class="intervention-info">
      <h3>mTOR Inhibition</h3>
      <p>Rapamycin and its analogs inhibit mTORC1, mimicking caloric restriction's effects on aging. The most consistent lifespan extension data in model organisms of any single known intervention.</p>
      <div class="intervention-meta">
        <div class="meta-item"><span class="meta-label">Status</span><span class="meta-value">Off-Label Use</span></div>
        <div class="meta-item"><span class="meta-label">Target</span><span class="meta-value">Nutrient Sensing</span></div>
        <div class="meta-item"><span class="meta-label">Animal Data</span><span class="meta-value">Excellent</span></div>
        <div class="meta-item"><span class="meta-label">Human Data</span><span class="meta-value">Promising</span></div>
      </div>
    </div>
    <div class="intervention-cards">
      <div class="intervention-card"><h4>Rapamycin</h4><p>mTORC1 inhibitor extending mouse lifespan by 9–14% even when started late in life. Growing human longevity community uses intermittent dosing protocols.</p></div>
      <div class="intervention-card"><h4>Rapalogs</h4><p>Second-generation mTOR inhibitors with improved selectivity, aiming to preserve longevity benefits while reducing immunosuppressive side effects.</p></div>
    </div>
  </div>

  <div id="tab-nad" class="tab-content">
    <div class="intervention-info">
      <h3>NAD+ Restoration</h3>
      <p>NAD+ levels decline dramatically with age, impairing sirtuin activity, DNA repair, and mitochondrial function. Precursors NMN and NR can measurably restore levels in human tissue.</p>
      <div class="intervention-meta">
        <div class="meta-item"><span class="meta-label">Status</span><span class="meta-value">Supplements + Trials</span></div>
        <div class="meta-item"><span class="meta-label">Target</span><span class="meta-value">Mitochondria + DNA Repair</span></div>
        <div class="meta-item"><span class="meta-label">Animal Data</span><span class="meta-value">Strong</span></div>
        <div class="meta-item"><span class="meta-label">Safety</span><span class="meta-value">Excellent</span></div>
      </div>
    </div>
    <div class="intervention-cards">
      <div class="intervention-card"><h4>NMN (Nicotinamide Mononucleotide)</h4><p>Direct NAD+ precursor showing improvements in muscle function, insulin sensitivity, and NAD+ blood levels in human clinical trials.</p></div>
      <div class="intervention-card"><h4>NR (Nicotinamide Riboside)</h4><p>Alternative NAD+ precursor with robust safety data and demonstrated ability to raise NAD+ in blood and multiple tissues.</p></div>
    </div>
  </div>
</section>

<!-- ROADMAP -->
<section class="roadmap-section" id="roadmap">
  <div class="section-tag fade-in">03 — The Timeline</div>
  <h2 class="fade-in">The Road to <em>Immortality</em></h2>
  <div class="timeline">
    <div class="timeline-item fade-in">
      <div class="timeline-year">NOW — 2030</div>
      <h3>The Compression Era</h3>
      <p>First senolytic therapies reach clinical approval. Rapamycin enters longevity trials. Partial reprogramming shows safety in primates. Biological age becomes a standard clinical biomarker. The first humans measurably reverse their biological age.</p>
    </div>
    <div class="timeline-item fade-in">
      <div class="timeline-year">2030 — 2040</div>
      <h3>The Rejuvenation Decade</h3>
      <p>Combination therapies targeting multiple hallmarks simultaneously achieve 20+ year biological age reversal in clinical settings. In vivo reprogramming reaches human trials. AI-designed longevity drugs compress decades of discovery into years.</p>
    </div>
    <div class="timeline-item fade-in">
      <div class="timeline-year">2040 — 2050</div>
      <h3>Escape Velocity</h3>
      <p>For every year a person lives, science adds more than one year to their remaining life expectancy. The first generation to live indefinitely is already alive today. Death from aging becomes a choice, not a certainty.</p>
    </div>
    <div class="timeline-item fade-in">
      <div class="timeline-year">2050+</div>
      <h3>The Post-Mortal World</h3>
      <p>Aging is classified as a fully treatable condition. The profound philosophical and societal questions of indefinite lifespans become humanity's central challenge. VECVO's mission is complete.</p>
    </div>
  </div>
</section>

<!-- FAQ -->
<section class="faq-section" id="faq">
  <div class="section-tag fade-in">04 — Questions</div>
  <h2 class="fade-in">Critical <em>Questions</em></h2>
  <div style="max-width:780px;">
    <div class="accordion-item fade-in">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <h4>Is defeating aging actually scientifically possible?</h4>
        <div class="accordion-icon">+</div>
      </div>
      <div class="accordion-body"><div class="accordion-body-inner">The scientific consensus has shifted dramatically. Aging is now understood as a biological process driven by identifiable molecular mechanisms — not a fixed law of nature. We have already reversed aging in model organisms. The 12 hallmarks provide a comprehensive mechanistic framework. The question is no longer "can we" but "how fast can we move."</div></div>
    </div>
    <div class="accordion-item fade-in">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <h4>What is longevity escape velocity?</h4>
        <div class="accordion-icon">+</div>
      </div>
      <div class="accordion-body"><div class="accordion-body-inner">Longevity escape velocity (LEV) is the point at which science extends human life expectancy faster than time passes. If you gain more than one year of healthy life expectancy for every year lived, you escape the mortality curve. Aubrey de Grey estimates LEV is achievable within decades with sufficient scientific investment.</div></div>
    </div>
    <div class="accordion-item fade-in">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <h4>Will AI dramatically accelerate longevity research?</h4>
        <div class="accordion-icon">+</div>
      </div>
      <div class="accordion-body"><div class="accordion-body-inner">AlphaFold's protein structure predictions transformed structural biology overnight. Similar breakthroughs in aging research could compress decades of work into years. AI systems are already identifying novel drug candidates, predicting treatment outcomes, and designing trials. The convergence of AI with aging biology may be the decisive catalyst.</div></div>
    </div>
    <div class="accordion-item fade-in">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <h4>Which single intervention has the greatest impact today?</h4>
        <div class="accordion-icon">+</div>
      </div>
      <div class="accordion-body"><div class="accordion-body-inner">Epigenetic reprogramming is considered most transformative as it addresses upstream information loss. Senolytics offer the clearest near-term clinical benefit. mTOR inhibition has the most consistent animal data. The current leading hypothesis is a combination approach: senolytics, rapamycin, NAD+ precursors, and epigenetic interventions together.</div></div>
    </div>
  </div>
</section>

<!-- COMPANIES -->
<section class="companies-section">
  <div class="section-tag fade-in" style="justify-content:center;">05 — The Ecosystem</div>
  <h2 class="fade-in">Pioneering <em>Organizations</em></h2>
  <p class="fade-in" style="max-width:560px;margin:0 auto;font-size:17px;color:var(--muted);line-height:1.85;">The longevity industry has attracted billions in capital. These organizations are pushing the frontier of aging science.</p>
  <div class="companies-grid fade-in">
    <div class="company-cell"><span class="company-name">ALTOS LABS</span><span class="company-focus">Epigenetic Reprogramming</span><span class="company-desc">$3B backed. Developing cellular rejuvenation programming to restore youthful biology.</span></div>
    <div class="company-cell"><span class="company-name">CALICO</span><span class="company-focus">Longevity Research</span><span class="company-desc">Google/Alphabet's longevity moonshot. Basic research into the biology of aging.</span></div>
    <div class="company-cell"><span class="company-name">UNITY BIOTECH</span><span class="company-focus">Senolytics</span><span class="company-desc">Clinical-stage company developing senolytic therapies for age-related diseases.</span></div>
    <div class="company-cell"><span class="company-name">RETRO BIOSCIENCES</span><span class="company-focus">Reprogramming</span><span class="company-desc">Sam Altman-backed. Partial cellular reprogramming and plasma dilution therapies.</span></div>
    <div class="company-cell"><span class="company-name">INSILICO MEDICINE</span><span class="company-focus">AI Drug Discovery</span><span class="company-desc">AI-powered aging target identification and drug candidate generation at scale.</span></div>
    <div class="company-cell"><span class="company-name">BIOAGE LABS</span><span class="company-focus">Biomarkers + Drugs</span><span class="company-desc">Machine learning on blood biomarkers to develop precision longevity therapies.</span></div>
    <div class="company-cell"><span class="company-name">SENS RESEARCH</span><span class="company-focus">Damage Repair</span><span class="company-desc">Targeting all 7 categories of age-related molecular damage for comprehensive repair.</span></div>
    <div class="company-cell"><span class="company-name">NEWLIMIT</span><span class="company-focus">Epigenetic Medicines</span><span class="company-desc">Coinbase-backed. Building epigenetic medicines to extend healthy human lifespan.</span></div>
  </div>
</section>

<!-- MANIFESTO -->
<section class="manifesto">
  <div class="manifesto-inner fade-in">
    <div class="section-tag" style="justify-content:center;margin-bottom:36px;">Our Belief</div>
    <div class="manifesto-quote">
      "Death is not <em>inevitable.</em> Aging is not natural law. It is a disease — and every disease has a cure. The greatest project in human history has already begun."
    </div>
    <p class="manifesto-sub">The science is ready. The technology is converging. The only question is how fast we move.</p>
    <a href="#aging" class="btn-primary"><span>Begin from the Start</span></a>
  </div>
</section>

<!-- FOOTER -->
<footer>
  <div class="footer-logo">
    <div class="f-dot"></div>
    VE<span>C</span>VO
  </div>
  <div class="footer-center">
    An open-source longevity research hub<br>
    Built for the pursuit of human immortality
  </div>
  <div class="footer-founder">
    <strong>ALICE FROLOV</strong>
    Founder & Researcher
  </div>
  <div class="footer-nav">
    <a href="#aging">Science</a>
    <a href="#interventions">Interventions</a>
    <a href="#roadmap">Roadmap</a>
    <a href="#faq">FAQ</a>
    <a href="#about">About</a>
  </div>
</footer>

<script>
// Cursor
const cursor = document.getElementById('cursor');
const ring = document.getElementById('cursorRing');
let mx = 0, my = 0, rx = 0, ry = 0;
document.addEventListener('mousemove', e => {
  mx = e.clientX; my = e.clientY;
  cursor.style.left = mx - 3 + 'px';
  cursor.style.top  = my - 3 + 'px';
});
(function tick() {
  rx += (mx - rx) * 0.12;
  ry += (my - ry) * 0.12;
  ring.style.left = rx + 'px';
  ring.style.top  = ry + 'px';
  requestAnimationFrame(tick);
})();
document.querySelectorAll('a,button,.accordion-header,.hallmark-card,.intervention-card,.company-cell').forEach(el => {
  el.addEventListener('mouseenter', () => {
    cursor.style.transform = 'scale(3)';
    ring.style.transform = 'translate(-50%,-50%) scale(1.4)';
    ring.style.borderColor = 'rgba(0,212,220,0.65)';
  });
  el.addEventListener('mouseleave', () => {
    cursor.style.transform = 'scale(1)';
    ring.style.transform = 'translate(-50%,-50%) scale(1)';
    ring.style.borderColor = 'rgba(0,212,220,0.35)';
  });
});

// Tabs
function switchTab(name, e) {
  document.querySelectorAll('.tab-content').forEach(t => t.classList.remove('active'));
  document.querySelectorAll('.tab-btn').forEach(b => b.classList.remove('active'));
  document.getElementById('tab-' + name).classList.add('active');
  e.target.classList.add('active');
}

// Accordion
function toggleAccordion(hdr) {
  const item = hdr.parentElement;
  const open = item.classList.contains('open');
  document.querySelectorAll('.accordion-item').forEach(i => i.classList.remove('open'));
  if (!open) item.classList.add('open');
}

// Fade in
const observer = new IntersectionObserver(entries => {
  entries.forEach(e => { if (e.isIntersecting) e.target.classList.add('visible'); });
}, { threshold: 0.08, rootMargin: '0px 0px -40px 0px' });
document.querySelectorAll('.fade-in').forEach(el => observer.observe(el));

// Counters
function counter(id, target, ms = 1800) {
  const el = document.getElementById(id);
  let v = 0, step = target / (ms / 16);
  const t = setInterval(() => {
    v += step;
    if (v >= target) { v = target; clearInterval(t); }
    el.textContent = Math.round(v);
  }, 16);
}
const statsObs = new IntersectionObserver(entries => {
  entries.forEach(e => {
    if (e.isIntersecting) {
      counter('stat1', 150);
      counter('stat2', 12);
      counter('stat3', 5);
      counter('stat4', 2050, 2400);
      statsObs.disconnect();
    }
  });
}, { threshold: 0.5 });
const sb = document.querySelector('.stat-bar');
if (sb) statsObs.observe(sb);

// Nav scroll
window.addEventListener('scroll', () => {
  const nav = document.querySelector('nav');
  nav.style.background = window.scrollY > 80
    ? 'rgba(3,4,10,0.97)'
    : 'linear-gradient(to bottom, rgba(3,4,10,0.96), transparent)';
  nav.style.borderBottom = window.scrollY > 80 ? '1px solid rgba(0,212,220,0.07)' : 'none';
});
</script>
</body>
</html>